Home Companies Catalysts Deep Dives
Lucentis ranibizumab APPROVED
Drug Profile
ModalityAntibody fragment
RouteIntravitreal
Therapy AreaOphthalmology
Launch2006-06-30
US LOE2020-06-30
Peak Sales Est$1500M
Formulations[{"id":"lucentis-intravitreal","doses":"0.5mg/0.05mL vial","route":"Intravitreal","setting":"HCP_ADM
Companies
ROG.SW (CO_DEVELOPER)50%
NVS (CO_DEVELOPER)50%
Mechanism: VEGF antagonist
Expert: Monoclonal antibody fragment targeting vascular endothelial growth factor A
Everyday: Blocks blood vessel growth in the eye to preserve vision
Targets: ["VEGF"]
Revenue History
PeriodRevenue ($M)
2024$680M
2025$520M
Programs (2)
IndicationStageKey StudyRegional Status
Wet AMDAPPROVEDMARINA/ANCHOR[{"stage":"APPROVED","region":"US","approval_date":"2006-06-30"},{"stage":"APPRO
DMEAPPROVEDRIDE/RISE[{"stage":"APPROVED","region":"US","approval_date":"2012-08-10"}]
Notes
Anti-VEGF for wet AMD. Partnered with Roche. Facing biosimilar competition.
Data from Supabase · Updated 2026-03-24